nach oben

Erschienen in:

17.02.2023 | Restless-Legs-Syndrom | Leitlinien

Restless Legs Syndrom

Leitlinien für Diagnostik und Therapie

verfasst von: PD Dr. A. Heidbreder, C. Trenkwalder, C. G. Bachmann, M. Bartl, S. Fulda, L. Habersack, C. Maihöfner, J. Mathis, L. Muntean, B. Schneider, A. Stefani, J. Paulus, P. Young

Erschienen in: Somnologie | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Auszug

Version 1.1 …

Gelegentlich fehlen die Missempfindungen der Beine, und der Bewegungsdrang der Beine tritt ohne diese auf. Neben den Beinen können auch andere Bereiche des Körpers von Beschwerden betroffen sein, z. B. Arme.

Bei sehr schweren Beschwerden kann die Verbesserung der Beschwerden durch Bewegung ausbleiben, sollte aber zu Beginn der Erkrankung vorhanden gewesen sein.

Bei sehr schweren Beschwerden kann die Verschlechterung der Beschwerden am Abend oder in der Nacht ausbleiben, sollte aber zu Beginn der Erkrankung vorhanden gewesen sein.

Diese Erkrankungen oder Umstände, oft als „RLS-Mimics“ bezeichnet, werden häufig mit RLS-Beschwerden verwechselt, da sie ähnliche Symptome aufweisen und oft die o. g. Kriterien 1–4 erfüllen. RLS kann natürlich auch im Rahmen anderer Erkrankungen auftreten, sollte aber, wenn die Diagnose RLS gestellt wird, dann im Ausmaß, Ausprägung oder Charakterisierung von der anderen komorbiden Erkrankung klar zu unterscheiden/abgrenzbar sein.

Die allermeisten Personen mit einem RLS werden durch RLS-Screeningfragebögen erkannt, da diese Instrumente eine hohe Sensitivität haben. In der Gruppe der Personen, die durch einen RLS-Screeningfragebogen identifiziert werden, haben jedoch die meisten Personen kein RLS, sondern z. B. RLS-Mimics (niedriger positiver prädiktiver Wert) [32].

325 mg Eisen-II-Sulfat (entspricht 65 mg Eisen-Ionen (Fe2+) (US-Präparate); entspricht 80 bis 100 mg Eisen-Ionen (Fe2+) (Präparate in Deutschland, Österreich und der Schweiz)).

Unter i.v.-Administration von hochmolekularen Eisendextranen können anaphylaktische Reaktionen auftreten, weshalb diese aufgrund des „nicht akzeptablen Risikos“ nicht eingesetzt werden sollten [77]. Hochmolekulare Eisendextrane sind in Deutschland allerdings nicht mehr zugelassen und somit auch nicht verfügbar.

Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW et al (2014) Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med 15(8):860–873PubMedCrossRef

American Academy of Sleep Medicine (2014) International classification of sleep disorders, 3. Aufl. AASM, Darien

Richards KC, Allen RP, Morrison J, Fry L, Kovach CR, Rangel A et al (2021) Nighttime agitation in persons with dementia as a manifestation of restless legs syndrome. J Am Med Dir Assoc 22(7):1410–1414PubMedCrossRef

Figorilli M, Puligheddu M, Ferri R (2015) Restless legs syndrome/Willis-Ekbom disease and periodic limb movements in sleep in the elderly with and without dementia. Sleep Med Clin 10(3):331–342 (xiv–xv)PubMedCrossRef

Boulos MI, Jairam T, Kendzerska T, Im J, Mekhael A, Murray BJ (2019) Normal polysomnography parameters in healthy adults: a systematic review and meta-analysis. Lancet Respir Med 7(6):533–543PubMedCrossRef

Gamaldo C, Benbrook AR, Allen RP, Oguntimein O, Earley CJ (2009) Evaluating daytime alertness in individuals with Restless Legs Syndrome (RLS) compared to sleep restricted controls. Sleep Med 10(1):134–138PubMedCrossRef

Turrini A, Raggi A, Calandra-Buonaura G, Martinelli P, Ferri R, Provini F (2018) Not only limbs in atypical restless legs syndrome. Sleep Med Rev 38:50–55PubMedCrossRef

Raggi A, Ferri R (2019) Phantom restless legs syndrome. Eur Neurol 81(5–6):302–308PubMedCrossRef

Salminen AV, Rimpilä V, Polo O (2014) Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease). Neurology 82(21):1856–1861PubMedCrossRef

10.

Castillo PR, Kaplan J, Lin SC, Fredrickson PA, Mahowald MW (2006) Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin Proc 81(10):1345–1347PubMedCrossRef

11.

Gupta R, Ulfberg J, Allen RP, Goel D (2017) High prevalence of Restless Legs Syndrome/Willis Ekbom Disease (RLS/WED) among people living at high altitude in the Indian Himalaya. Sleep Med 35:7–11PubMedCrossRef

12.

Wåhlin-Larsson B, Ulfberg J, Aulin KP, Kadi F (2009) The expression of vascular endothelial growth factor in skeletal muscle of patients with sleep disorders. Muscle Nerve 40(4):556–561PubMedCrossRef

13.

Patton SM, Ponnuru P, Snyder AM, Podskalny GD, Connor JR (2011) Hypoxia-inducible factor pathway activation in restless legs syndrome patients. Eur J Neurol 18(11):1329–1335PubMedCrossRef

14.

Winkelmann J, Ferini-Strambi L (2006) Genetics of restless legs syndrome. Sleep Med Rev 10(3):179–183PubMedCrossRef

15.

Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B et al (2017) Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol. https://doi.org/10.1016/S1474-4422(17)30327-7CrossRefPubMedPubMedCentral

16.

Akçimen F, Sarayloo F, Liao C, Ross JP, Oliveira RDB, Dion PA et al (2020) Transcriptome-wide association study for restless legs syndrome identifies new susceptibility genes. Commun Biol 3(1):373PubMedPubMedCentralCrossRef

17.

Ferré S, García-Borreguero D, Allen RP, Earley CJ (2019) New insights into the neurobiology of restless legs syndrome. Neuroscientist 25(2):113–125PubMedCrossRef

18.

Haschka D, Volani C, Stefani A, Tymoszuk P, Mitterling T, Holzknecht E et al (2019) Association of mitochondrial iron deficiency and dysfunction with idiopathic restless legs syndrome. Mov Disord 34(1):114–123PubMedCrossRef

19.

Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC et al (2014) Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med 15(11):1288–1301PubMedCrossRef

20.

Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT et al (2009) Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 132(Pt 9):2403–2412PubMedPubMedCentralCrossRef

21.

Earley CJ, Uhl GR, Clemens S, Ferré S (2017) Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Med 31:71–77PubMedCrossRef

22.

Rizzo G, Li X, Galantucci S, Filippi M, Cho YW (2017) Brain imaging and networks in restless legs syndrome. Sleep Med 31:39–48PubMedCrossRef

23.

Stefani A, Mitterling T, Heidbreder A, Steiger R, Kremser C, Frauscher B et al (2019) Multimodal magnetic resonance imaging reveals alterations of sensorimotor circuits in restless legs syndrome. Sleep. https://doi.org/10.1093/sleep/zsz171CrossRefPubMed

24.

Kocar TD, Müller HP, Kassubek J (2020) Differential functional connectivity in thalamic and dopaminergic pathways in restless legs syndrome: a meta-analysis. Ther Adv Neurol Disord 13:1756286420941670PubMedPubMedCentralCrossRef

25.

Tuovinen N, Stefani A, Mitterling T, Heidbreder A, Frauscher B, Gizewski ER et al (2021) Functional connectivity and topology in patients with restless legs syndrome: a case-control resting-state functional magnetic resonance imaging study. Eur J Neurol 28(2):448–458PubMedCrossRef

26.

Lee YS, Ku J, Kim KT, Chang H, Earley CJ, Allen RP et al (2020) Resting-state connectivity and the effects of treatment in restless legs syndrome. Sleep Med 67:33–38PubMedCrossRef

27.

Ferri R, Fulda S, Allen RP, Zucconi M, Bruni O, Chokroverty S et al (2016) World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). Sleep Med 26:86–95PubMedCrossRef

28.

AWMF (2020) Schlafbezogene Atmungsstörungen bei Erwachsenen. In: S3-Leitlinie: Nicht erholsamer Schlaf/Schlafstörungen

29.

Riemann D (2017) S3-Leitlinie: Nicht erholsamer Schlaf/Schlafstörungen, Kapitel „Insomnie bei Erwachsenen“, Update 2016. Somnologie 21:2–44CrossRef

30.

Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ et al (2018) Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 41:27–44PubMedCrossRef

31.

Leclair-Visonneau L, Vecchierini MF, Schröder C, Charley Monaca C (2018) French consensus: How to diagnose restless legs syndrome. Rev Neurol (Paris) 174(7–8):508–514PubMedCrossRef

32.

Fulda S, Allen RP, Earley CJ, Högl B, Garcia-Borreguero D, Inoue Y et al (2021) We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. Sleep Med Rev 58:101461PubMedCrossRef

33.

Berger K, von Eckardstein A, Trenkwalder C, Rothdach A, Junker R, Weiland SK (2002) Iron metabolism and the risk of restless legs syndrome in an elderly general population—the MEMO-Study. J Neurol 249(9):1195–1199PubMedCrossRef

34.

Benes H, Kohnen R (2009) Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med 10(5):515–523PubMedCrossRef

35.

Stiasny-Kolster K, Möller JC, Heinzel-Gutenbrunner M, Baum E, Ries V, Oertel WH (2009) Validation of the restless legs syndrome screening questionnaire (RLSSQ). Somnologie 13:37–42CrossRef

36.

Stiasny-Kolster K, Kohnen R, Möller JC, Trenkwalder C, Oertel WH (2006) Validation of the „L-DOPA test“ for diagnosis of restless legs syndrome. Mov Disord 21(9):1333–1339PubMedCrossRef

37.

Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP et al (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4(2):121–132PubMedCrossRef

38.

Kohnen R, Martinez-Martin P, Benes H, Trenkwalder C, Högl B, Dunkl E et al (2016) Rating of daytime and nighttime symptoms in RLS: validation of the RLS‑6 scale of restless legs syndrome/Willis-Ekbom disease. Sleep Med 20:116–122PubMedCrossRef

39.

García-Borreguero D, Kohnen R, Högl B, Ferini-Strambi L, Hadjigeorgiou GM, Hornyak M et al (2007) Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8(5):455–463PubMedCrossRef

40.

Sharon D, Allen RP, Martinez-Martin P, Walters AS, Ferini Strambi L, Högl B et al (2019) Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale—The sIRLS. Sleep Med 54:94–100PubMedCrossRef

41.

Szentkirályi A, Völzke H, Hoffmann W, Trenkwalder C, Berger K (2014) Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies. Neurology 82(22):2026–2033PubMedCrossRef

42.

Wipper B, Winkelman JW (2021) The long-term psychiatric and cardiovascular morbidity and mortality of restless legs syndrome and periodic limb movements of sleep. Sleep Med Clin 16(2):279–288PubMedCrossRef

43.

Bartl M, Winkelmann J, Högl B, Paulus W, Trenkwalder C (2018) Frequent neurological diseases associated with the restless legs syndrome. Nervenarzt 89(10):1156–1164PubMedCrossRef

44.

Trenkwalder C, Allen R, Högl B, Clemens S, Patton S, Schormair B et al (2018) Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol 17(11):994–1005PubMedCrossRef

45.

Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J (2016) Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology 86(14):1336–1343PubMedPubMedCentralCrossRef

46.

Garcia-Malo C, Wanner V, Miranda C, Romero Peralta S, Agudelo L, Cano-Pumarega I et al (2020) Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. Sleep Med 66:123–129PubMedCrossRef

47.

Mao S, Shen H, Huang S, Zhang A (2014) Restless legs syndrome in dialysis patients: a meta-analysis. Sleep Med 15(12):1532–1538PubMedCrossRef

48.

Lopez R, Micoulaud Franchi JA, Chenini S, Gachet M, Jaussent I, Dauvilliers Y (2019) Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder. Sleep 42(5):zsz27PubMedCrossRef

49.

Ghanei Gheshlagh R, Farajzadeh M, Zarei M, Baghi V, Dalvand S, Sayehmiri K (2017) The prevalence of restless legs syndrome in patients undergoing hemodialysis: a systematic review and meta-analysis study. Basic Clin Neurosci 8(2):105–112PubMedPubMedCentralCrossRef

50.

Gupta R, Gupta R, Kumar N, Rawat VS, Ulfberg J, Allen RP (2021) Restless legs syndrome among subjects having chronic liver disease: A systematic review and meta-analysis. Sleep Med Rev 58:101463PubMedCrossRef

51.

Mathis J (2014) Restless Legs Syndrom, Klinik, Ätiologie, Pathophysiologie, Abklärung, Therapie, Kasuistiken. Differentialdiagnose Und Abklärung. UNI-MED Science, Bremen

52.

Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG (2021) Association between restless legs syndrome and peripheral neuropathy: A systematic review and meta-analysis. Eur J Neurol 28(7):2423–2442PubMedCrossRef

53.

Hattan E, Chalk C, Postuma RB (2009) Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology 72(11):955–960PubMedCrossRef

54.

Happe S, Zeitlhofer J (2003) Abnormal cutaneous thermal thresholds in patients with restless legs syndrome. J Neurol 250(3):362–365PubMedCrossRef

55.

Bergmann M, Heidbreder A, Stefani A, Raccagni C, Brandauer E, Rudzki D et al (2021) Signs of sympathetic and endothelial cell activation in the skin of patients with restless legs syndrome. Sleep Med 84:227–236PubMedCrossRef

56.

Alonso-Navarro H, García-Martín E, Agúndez JAG, Jiménez-Jiménez FJ (2019) Association between restless legs syndrome and other movement disorders. Neurology 92(20):948–964PubMedCrossRef

57.

Stefani A, Högl B (2020) Sleep in Parkinson’s disease. Neuropsychopharmacology 45(1):121–128PubMedCrossRef

58.

Ozdogar AT, Kalron A (2021) Restless legs syndrome in people with multiple sclerosis: An updated systematic review and meta-analyses. Mult Scler Relat Disord 56:103275PubMedCrossRef

59.

Ghasemi H, Khaledi-Paveh B, Abdi A, Jalali R, Salari N, Vaisi-Raygani A et al (2020) The prevalence of restless legs syndrome in patients with migraine: a systematic review and meta-analysis. Pain Res Manag 2020:2763808PubMedPubMedCentralCrossRef

60.

Black J, Reaven NL, Funk SE, McGaughey K, Ohayon MM, Guilleminault C et al (2017) Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med 33:13–18PubMedCrossRef

61.

Mathias JL, Cant ML, Burke ALJ (2018) Sleep disturbances and sleep disorders in adults living with chronic pain: a meta-analysis. Sleep Med 52:198–210PubMedCrossRef

62.

Green ME, Bernet V, Cheung J (2021) Thyroid dysfunction and sleep disorders. Front Endocrinol 12:725829CrossRef

63.

Thi Truong BE, Sung FC, Lin CL, Hang LW, Teng YK, Tzeng YL (2021) A follow-up study on restless legs syndrome in chronic obstructive pulmonary disease population. Sleep Med 80:9–15PubMedCrossRef

64.

Gupta MA, Simpson FC, Gupta AK (2016) Psoriasis and sleep disorders: A systematic review. Sleep Med Rev 29:63–75PubMedCrossRef

65.

Guo J, Pei L, Chen L, Chen H, Gu D, Peng Y et al (2021) Bidirectional association between irritable bowel syndrome and restless legs syndrome: a systematic review and meta-analysis. Sleep Med 77:104–111PubMedCrossRef

66.

Kolla BP, Mansukhani MP, Bostwick JM (2018) The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review. Sleep Med Rev 38:131–140PubMedCrossRef

67.

Mathis J, Meichtry J (2021) Auf Komorbiditäten achten: Restless-Legs-Syndrom – Diagnostik und Therapie. BrainMAG 6:44–50

68.

Schlereth T (2020) S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen. DGNeurologie 3(1):21–40CrossRef

69.

Oksenberg A (2010) Alleviation of severe restless legs syndrome (RLS) symptoms by cigarette smoking. J Clin Sleep Med 6(5):489–490PubMedPubMedCentralCrossRef

70.

Berger K, Kurth T (2007) RLS epidemiology—frequencies, risk factors and methods in population studies. Mov Disord 22(Suppl 18):S420–S423PubMedCrossRef

71.

Trenkwalder C, Tinelli M, Sakkas GK, Dauvilliers Y, Ferri R, Rijsman R et al (2021) Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings. Eur J Neurol 28(2):691–706PubMedCrossRef

72.

Boulos MI, Wan A, Black SE, Lim AS, Swartz RH, Murray BJ (2017) Restless legs syndrome after high-risk TIA and minor stroke: association with reduced quality of life. Sleep Med 37:135–140PubMedCrossRef

73.

Duarte GS, Alves M, Silva MA, Camara R, Caldeira D, Ferreira JJ (2020) Cardiovascular events reported in randomized controlled trials in restless legs syndrome. Sleep Med 65:13–17PubMedCrossRef

74.

Ferini-Strambi L, Walters AS, Sica D (2014) The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol 261(6):1051–1068PubMedCrossRef

75.

Trotti LM, Becker LA (2019) Iron for the treatment of restless legs syndrome. Cochrane Database Syst Rev 1(1):CD7834PubMed

76.

Trenkwalder C, Winkelmann J, Oertel W, Virgin G, Roubert B, Mezzacasa A (2017) Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Mov Disord 32(10):1478–1482PubMedPubMedCentralCrossRef

77.

Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV et al (2018) Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)(§). Mov Disord 33(7):1077–1091PubMedCrossRef

78.

Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M (2011) Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011(3):CD6009PubMedPubMedCentral

79.

Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E et al (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41(1):19–75PubMedCrossRef

80.

Pourcher E, Rémillard S, Cohen H (2010) Compulsive habits in restless legs syndrome patients under dopaminergic treatment. J Neurol Sci 290(1–2):52–56PubMedCrossRef

81.

Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M et al (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11PubMedCrossRef

82.

Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W et al (2011) Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 10(8):710–720PubMedCrossRef

83.

Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E et al (2016) Rotigotine in hemodialysis-associated restless legs syndrome: a randomized controlled trial. Am J Kidney Dis 68(3):434–443PubMedCrossRef

84.

Liu GJ, Wu L, Wang SL, Ding L, Xu LL, Wang YF et al (2016) Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine (Baltimore) 95(2):e2504PubMedCrossRef

85.

Bauer A, Cassel W, Benes H, Kesper K, Rye D, Sica D et al (2016) Rotigotine’s effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT. Neurology 86(19):1785–1793PubMedPubMedCentralCrossRef

86.

Kurin M, Bielefeldt K, Levinthal DJ (2018) Prevalence of nausea and vomiting in adults using ropinirole: a systematic review and meta-analysis. Dig Dis Sci 63(3):687–693PubMedCrossRef

87.

Kaye CM, Nicholls B (2000) Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39(4):243–254PubMedCrossRef

88.

Anderson GD, Chan LN (2016) Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 55(11):1353–1368PubMedCrossRef

89.

Juergens TM (2008) Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation. J Clin Sleep Med 4(4):371–372PubMedPubMedCentralCrossRef

90.

Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J et al (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 370(7):621–631PubMedCrossRef

91.

Allen RP (2014) Restless legs syndrome/Willis Ekbom disease: evaluation and treatment. Int Rev Psychiatry 26(2):248–262PubMedCrossRef

92.

Manconi M, Ferri R, Zucconi M, Oldani A, Giarolli L, Bottasini V et al (2011) Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. Mov Disord 26(5):892–895PubMedCrossRef

93.

Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C et al (2016) Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 87(24):2585–2593PubMedPubMedCentralCrossRef

94.

Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C et al (2014) Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep 37(4):635–643PubMedPubMedCentralCrossRef

95.

Bogan RK, Bornemann MAC, Kushida CA, Trân PV, Barrett RW (2010) Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 85(6):512–521PubMedPubMedCentralCrossRef

96.

Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W et al (2012) A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol 35(4):165–173PubMedCrossRef

97.

Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW (2011) A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 7(3):282–292PubMedPubMedCentralCrossRef

98.

Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M et al (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12(12):1141–1150PubMedCrossRef

99.

Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M et al (2001) Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 16(6):1105–1109PubMedCrossRef

100.

Rose AR, Catcheside PG, McEvoy RD, Paul D, Kapur D, Peak E et al (2014) Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long term opioid therapy. J Clin Sleep Med 10(8):847–852PubMedPubMedCentralCrossRef

101.

Colvin LA, Bull F, Hales TG (2019) Perioperative opioid analgesia—when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet Lond Engl 393(10180):1558–1568CrossRef

102.

Hoque R, Chesson ALJ (2010) Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 6(1):79–83PubMedPubMedCentralCrossRef

103.

Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS et al (2020) Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Med Rev 53:101339PubMedCrossRef

104.

Marshall NS, Serinel Y, Killick R, Child JM, Raisin I, Berry CM et al (2019) Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review. Sleep Med Rev 48:101218PubMedCrossRef

105.

Carlos K, Prado GF, Teixeira CD, Conti C, de Oliveira MM, Prado LB et al (2017) Benzodiazepines for restless legs syndrome. Cochrane Database Syst Rev 3(3):CD6939PubMed

106.

Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, Kyriakides T et al (2013) Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol 14:194PubMedPubMedCentralCrossRef

107.

Innes KE, Selfe TK (2012) The effects of a gentle yoga program on sleep, mood, and blood pressure in older women with restless legs syndrome (RLS): a preliminary randomized controlled trial. Evid Based Complement Alternat Med 2012:294058PubMedPubMedCentralCrossRef

108.

Innes KE, Selfe TK, Montgomery C, Hollingshead N, Huysmans Z, Srinivasan R et al (2020) Effects of a 12-week yoga versus a 12-week educational film intervention on symptoms of restless legs syndrome and related outcomes: an exploratory randomized controlled trial. J Clin Sleep Med 16(1):107–119PubMedPubMedCentralCrossRef

109.

Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B (2006) Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 19(5):487–493PubMedCrossRef

110.

Heide AC, Winkler T, Helms HJ, Nitsche MA, Trenkwalder C, Paulus W et al (2014) Effects of transcutaneous spinal direct current stimulation in idiopathic restless legs patients. Brain Stimul 7(5):636–642PubMedCrossRef

111.

Zeng M, Wang L, Cheng B, Qi G, He J, Xu Z et al (2020) Transcutaneous spinal cord direct-current stimulation modulates functional activity and integration in idiopathic restless legs syndrome. Front Neurosci 14:873PubMedPubMedCentralCrossRef

112.

Mohammadi MM, Raygani AAV, Ghobadi A, Samadzadeh S, Salari N (2018) Effect of near-infrared light therapy based on acupoints on the severity of restless legs syndrome in patients undergoing hemodialysis: a single-blind, randomized controlled trial. Clin Med Res 16(1–2):1–8PubMedPubMedCentralCrossRef

113.

Mitchell UH, Johnson AW, Myrer B (2011) Comparison of two infrared devices in their effectiveness in reducing symptoms associated with RLS. Physiother Theory Pract 27(5):352–359PubMedCrossRef

114.

Mitchell UH, Myrer JW, Johnson AW, Hilton SC (2011) Restless legs syndrome and near-infrared light: An alternative treatment option. Physiother Theory Pract 27(5):345–351PubMedCrossRef

115.

Guffey JS, Motts S, Barymon D, Wooten A, Clough T, Payne E et al (2016) Using near infrared light to manage symptoms associated with restless legs syndrome. Physiother Theory Pract 32(1):34–44PubMedCrossRef

116.

Xu XM, Liu Y, Jia SY, Dong MX, Cao D, Wei YD (2018) Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review. Sleep Med Rev 38:158–167PubMedCrossRef

117.

Hayes CA, Kingsley JR, Hamby KR, Carlow J (2008) The effect of endovenous laser ablation on restless legs syndrome. Phlebology 23(3):112–117PubMedCrossRef

118.

Happe S, Evers S, Thiedemann C, Bunten S, Siegert R (2016) Whole body and local cryotherapy in restless legs syndrome: A randomized, single-blind, controlled parallel group pilot study. J Neurol Sci 370:7–12PubMedCrossRef

119.

Lettieri CJ, Eliasson AH (2009) Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest 135(1):74–80PubMedCrossRef

120.

Cui Y, Wang Y, Liu Z (2008) Acupuncture for restless legs syndrome. Cochrane Database Syst Rev 4:CD6457

121.

Pan W, Wang M, Li M, Wang Q, Kwak S, Jiang W et al (2015) Actigraph evaluation of acupuncture for treating restless legs syndrome. Evid Based Complement Alternat Med 2015:343201PubMedPubMedCentralCrossRef

122.

Kwon S, Jin C, Cho SY, Park SU, Jung WS, Moon SK et al (2019) Paeoniae Radix-containing herbal medicine for patients with restless legs syndrome: A systematic review and meta-analysis. Complement Ther Clin Pract 35:329–341PubMedCrossRef

123.

Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4(2):101–119PubMedCrossRef

124.

Chokroverty S (2015) Opioid-induced hyperalgesia and dopamine-induced augmentation in an intractable and refractory case of RLS. Sleep Med 16(10):1304PubMedCrossRef

125.

Högl B, García-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M et al (2010) Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 257(2):230–237PubMedCrossRef

126.

Trenkwalder C, Canelo M, Lang M, Schroeder H, Kelling D, Berkels R et al (2017) Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med 30:257–265PubMedCrossRef

127.

Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V (2019) Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med 55:74–80PubMedCrossRef

128.

Darvishi N, Daneshkhah A, Khaledi-Paveh B, Vaisi-Raygani A, Mohammadi M, Salari N et al (2020) The prevalence of Restless Legs Syndrome/Willis-Ekbom disease (RLS/WED) in the third trimester of pregnancy: a systematic review. BMC Neurol 20(1):132PubMedPubMedCentralCrossRef

129.

Chen SJ, Shi L, Bao YP, Sun YK, Lin X, Que JY et al (2018) Prevalence of restless legs syndrome during pregnancy: A systematic review and meta-analysis. Sleep Med Rev 40:43–54PubMedCrossRef

130.

Picchietti DL, Hensley JG, Bainbridge JL, Lee KA, Manconi M, McGregor JA et al (2015) Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev 22:64–77PubMedCrossRef

131.

Delgado Rodrigues RN, Alvim de Abreu E, Silva Rodrigues AA, Pratesi R, Krieger J (2006) Outcome of restless legs severity after continuous positive air pressure (CPAP) treatment in patients affected by the association of RLS and obstructive sleep apneas. Sleep Med 7(3):235–239PubMedCrossRef

132.

Auerbach M, Adamson JW (2016) How we diagnose and treat iron deficiency anemia. Am J Hematol 91(1):31–38PubMedCrossRef

133.

Breymann C, Honegger C, Hösli I, Surbek D (2017) Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum. Arch Gynecol Obstet 296(6):1229–1234PubMedCrossRef

134.

Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J (2014) Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatr 168(4):313–320PubMedCrossRef

135.

Eroglu C, Allen NJ, Susman MW, O’Rourke NA, Park CY, Ozkan E et al (2009) Gabapentin receptor alpha2delta‑1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 139(2):380–392PubMedPubMedCentralCrossRef

136.

Yilmaz K, Kilincaslan A, Aydin N, Kor D (2011) Prevalence and correlates of restless legs syndrome in adolescents. Dev Med Child Neurol 53(1):40–47PubMedCrossRef

137.

Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A, Ferini-Strambi L (2007) Restless legs syndrome: prevalence and impact in children and adolescents—the Peds REST study. Pediatrics 120(2):253–266PubMedCrossRef

138.

Walters AS, Hickey K, Maltzman J, Verrico T, Joseph D, Hening W et al (1996) A questionnaire study of 138 patients with restless legs syndrome: the „Night-Walkers“ survey. Neurology 46(1):92–95PubMedCrossRef

139.

Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P (1997) Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12(1):61–65PubMedCrossRef

140.

Muhle H, Neumann A, Lohmann-Hedrich K, Lohnau T, Lu Y, Winkler S et al (2008) Childhood-onset restless legs syndrome: clinical and genetic features of 22 families. Mov Disord 23(8):1113–1121PubMedCrossRef

141.

Picchietti DL, Bruni O, de Weerd A, Durmer JS, Kotagal S, Owens JA et al (2013) Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med 14(12):1253–1259PubMedCrossRef

142.

Ipsiroglu OS, Beyzaei N, Berger M, Wagner AL, Dhalla S, Garden J et al (2016) „Emplotted narratives“ and structured „behavioral observations“ supporting the diagnosis of Willis-Ekbom disease/restless legs syndrome in children with Neurodevelopmental conditions. CNS Neurosci Ther 22(11):894–905PubMedPubMedCentralCrossRef

143.

DelRosso LM, Bruni O, Ferri R (2018) Restless sleep disorder in children: a pilot study on a tentative new diagnostic category. Sleep. https://doi.org/10.1093/sleep/zsy102CrossRefPubMed

144.

Amos LB, Grekowicz ML, Kuhn EM, Olstad JD, Collins MM, Norins NA et al (2014) Treatment of pediatric restless legs syndrome. Clin Pediatr (Phila) 53(4):331–336PubMedCrossRef

145.

Furudate N, Komada Y, Kobayashi M, Nakajima S, Inoue Y (2014) Daytime dysfunction in children with restless legs syndrome. J Neurol Sci 336(1–2):232–236PubMedCrossRef

146.

Rosen GM, Morrissette S, Larson A, Stading P, Barnes TL (2019) Does improvement of low serum ferritin improve symptoms of restless legs syndrome in a cohort of pediatric patients? J Clin Sleep Med 15(8):1149–1154PubMedPubMedCentralCrossRef

147.

Dye TJ, Jain SV, Simakajornboon N (2017) Outcomes of long-term iron supplementation in pediatric restless legs syndrome/periodic limb movement disorder (RLS/PLMD). Sleep Med 32:213–219PubMedCrossRef

148.

Gurbani N, Dye TJ, Dougherty K, Jain S, Horn PS, Simakajornboon N (2019) Improvement of parasomnias after treatment of restless leg syndrome/periodic limb movement disorder in children. J Clin Sleep Med 15(5):743–748PubMedPubMedCentralCrossRef

149.

Tilma J, Tilma K, Norregaard O, Ostergaard JR (1992) Early childhood-onset restless legs syndrome: symptoms and effect of oral iron treatment. Acta Paediatr 102(5):e221–e226CrossRef

150.

Mohri I, Kato-Nishimura K, Kagitani-Shimono K, Kimura-Ohba S, Ozono K, Tachibana N et al (2012) Evaluation of oral iron treatment in pediatric restless legs syndrome (RLS). Sleep Med 13(4):429–432PubMedCrossRef

151.

Halac G, Sezer GM, Saglam NO, Tekturk P, Demir AD, Demir S et al (2015) The relationship between Willis-Ekbom disease and serum ferritin levels among children in Northwestern Turkey. Neurosciences 20(4):336–340PubMedPubMedCentralCrossRef

152.

Hulthén L, Lindstedt G, Lundberg PA, Hallberg L (1998) Effect of a mild infection on serum ferritin concentration—clinical and epidemiological implications. Eur J Clin Nutr 52(5):376–379PubMedCrossRef

153.

Lönnerdal B (2017) Excess iron intake as a factor in growth, infections, and development of infants and young children. Am J Clin Nutr 106(Suppl 6):1681S–1687SPubMedPubMedCentralCrossRef

154.

155.

Grim K, Lee B, Sung AY, Kotagal S (2013) Treatment of childhood-onset restless legs syndrome and periodic limb movement disorder using intravenous iron sucrose. Sleep Med 14(11):1100–1104PubMedCrossRef

156.

Pinsk V, Levy J, Moser A, Yerushalmi B, Kapelushnik J (2008) Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia. Isr Med Assoc J 10(5):335–338PubMed

157.

DelRosso L, Bruni O (2019) Treatment of pediatric restless legs syndrome. Adv Pharmacol 84:237–253PubMedCrossRef

158.

England SJ, Picchietti DL, Couvadelli BV, Fisher BC, Siddiqui F, Wagner ML et al (2011) L‑Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children. Sleep Med 12(5):471–477PubMedPubMedCentralCrossRef

159.

Elshoff JP, Hudson J, Picchietti DL, Ridel K, Walters AS, Doggett K et al (2017) Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease). Sleep Med 32:48–55PubMedCrossRef

160.

Simakajornboon N, Kheirandish-Gozal L, Gozal D (2009) Diagnosis and management of restless legs syndrome in children. Sleep Med Rev 13(2):149–156PubMedPubMedCentralCrossRef

161.

Picchietti MA, Picchietti DL (2008) Restless legs syndrome and periodic limb movement disorder in children and adolescents. Semin Pediatr Neurol 15(2):91–99PubMedCrossRef

162.

Hysing M, Pallesen S, Stormark KM, Jakobsen R, Lundervold AJ, Sivertsen B (2015) Sleep and use of electronic devices in adolescence: results from a large population-based study. BMJ Open 5(1):e6748PubMedPubMedCentralCrossRef

Titel: Restless Legs Syndrom
Leitlinien für Diagnostik und Therapie
verfasst von: PD Dr. A. Heidbreder
C. Trenkwalder
C. G. Bachmann
M. Bartl
S. Fulda
L. Habersack
C. Maihöfner
J. Mathis
L. Muntean
B. Schneider
A. Stefani
J. Paulus
P. Young
Publikationsdatum: 17.02.2023
Verlag: Springer Medizin
Schlagwörter: Restless-Legs-Syndrom
Dopaminagonisten
Erschienen in: Somnologie / Ausgabe 1/2023
Print ISSN: 1432-9123
Elektronische ISSN: 1439-054X
DOI: https://doi.org/10.1007/s11818-023-00399-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Schlafstörungen bei neuromuskulären Erkrankungen

Die schlafmedizinische Versorgung in Deutschland

Obstruktive Schlafapnoe und arterielle Hypertonie

Subtypen der Insomnie – exemplarische Ansätze und offene Fragen

Ein Umdenken in der Behandlung des Restless-Legs-Syndroms